Ypsomed grows and creates 102 new jobs

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SWX: YPSN) increased sales by 4.6% or CHF 8.7 million in the first six months of 2020/21 compared to the previous year, and generated an operating profit (EBIT) of CHF 8.3 million. The company continued on its growth course in a challenging environment, driving forward all strategic initiatives and creating 102 new jobs at the same time.

Leer más...

Ypsomed y Dexcom se asocian para impulsar el sistema closed loop (circuito cerrado)

Noticias Ypsomed España

Burgdorf / San Diego - Ypsomed (SWX: YPSN) y DexCom Inc. (NASDAQ: DXCM), el proveedor líder mundial de sistemas de monitorización continua de glucosa (CGM), anuncian su acuerdo para impulsar el desarrollo de un sistema híbrido de circuito cerrado. Esta colaboración es un hito importante en el desarrollo posterior de la terapia individualizada para la diabetes. En un primer paso, los datos del CGM de Dexcom se integrarán en la aplicación mylife de Ypsomed.

Leer más...

Teva has announced the launch of AJOVY in an autoinjector device for the German market in March 2020.
AJOVY autoinjector

Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed

Press Releases Ypsomed Group

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including central nervous system, pain and respiratory, launches its drug product AJOVY® in the pre-filled YpsoMate 2.25 autoinjector from Ypsomed. AJOVY® is used for the preventive treatment of migraine in adults. The collaboration with Teva marks the first commercial market entry of Ypsomed’s larger 2.25 ml autoinjector YpsoMate 2.25.

Leer más...

COVID-19 business continuity

Press Releases Ypsomed Group

We are monitoring the global development after the outbreak of the Coronavirus very closely. Our highest priority is our business continuity and the reliable supply of our products as well as the safety of our employees. We can confirm that to date there is no impact on the supply of our products and that our production sites are fully operational.

Leer más...

Delay in pump sales and strong growth in pharma customer business

Press Releases Ypsomed Group

Burgdorf – Ypsomed is recording weaker growth in the insulin pump business and is adjusting its approval strategy with the American FDA. In addition, Ypsomed is reducing its EBIT outlook for the current financial year 2019/20 to CHF 9 million due to one-time and temporary effects. Ypsomed confirms its mid-term EBIT target of CHF 100 million.

Leer más...